Evaluating Transcervical Lymphadenectomy in Systematic Diagnosis of Lung Cancer

² Universidad de Ciencias Médicas de Camagüey, Hospital Universitario Manuel Ascunce Domenech, Servicio de Anestesiología y Reanimación, Camagüey, Cuba

CP 2021, 3(3), 1–8; https://doi.org/10.18063/cp.v3i3.348

© Invalid date by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

XML

Cite

Abstract

Background: The study of mediastinal lymph node metastasis in patients with lung cancer is very important to formulate treatment strategies. Objective: To explore the value of transcervical lymphadenectomy in the systematic diagnosis of lung cancer. Methods: Transcervical lymphadenectomy was used as part of the systematic diagnosis of lung cancer in Hospital Universitario Manuel Ascunce Domenech in Camagüey. The universe consisted of 346 patients and the sample was a simple random probability type, consisting of 65 patients. Results: It was mainly male, over 60 years old. The most common histological type is adenocarcinoma, and the upper lobe is the most affected. A total of 205 lymph nodes were resected, most of which were positive and histologically negative, mainly in lymph nodes less than 1 cm diagnosed by CT. Staging metastasis existed in clinicopathological correlation, and the sensitivity and specificity of the study sample were 100%. There are few complications. Conclusion: Transcervical lymphadenectomy is an effective method for the diagnosis of lung cancer and mediastinal lymph node metastasis.

Keywords

Lung neoplasms/surgery

Lung neoplasms/complications

Lung neoplasms/imaging diagnosis

Lymph node resection/method

Longitudinal study

References

Siegel RL, Miller KD, Jemal A, 2018, Cancer Statistics, 2018. CA Cancer J Clin, 68:7–30. DOI: 10.3322/caac.21442.

Bray F, Ferlay J, Soerjomataram I, et al., 2018, Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 68:394–424. DOI: 10.3322/caac.21492.

Radovic M, Kanesvaran R, Rittmeyer A, et al., 2019, Multidisciplinary Treatment of Lung Cancer in Older Patients: A Review. J Geriatr Oncol, 10:405–10. DOI: 10.1016/j.jgo.2018.09.005.

Edwards JG, Chansky K, Van Schil P, et al., 2020, The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer. J Thorac Oncol, 15:344–59. DOI: 10.1016/j.jtho.2019.10.019.

Fernandez FG, Kosinski AS, Furnary AP, et al., 2018, Differential Effects of Operative Complications on Survival after Surgery for Primary Lung Cancer. J Thorac Cardiovasc Surg, 155:1254–64. DOI: 10.1016/j.jtcvs.2017.09.149.

Huang M, Manuballa S, Demmy T, et al., 2013, Transcervical Extended Mediastinal Lymphadenectomy-Indications and Technique. Indian J Surg Oncol, 4:138–41. DOI: 10.1007/s13193-013-0220-4.

Pérez-Alonso D, Hernández-Escobar F, López-Rivero L, 2016, Incisional Metastasis from Lung Cancer after Transcervical Extended Mediastinal Lymphadenectomy. Arch Bronconeumol, 52:276–7. DOI: 10.1016/j.arbres.2015.07.001.

Yendamuri S, Battoo A, Dy G, et al., 2017, Transcervical Extended Mediastinal Lymphadenectomy: Experience from a North American Cancer Center. Ann Thorac Surg, 104:1644–9. DOI: 10.1016/j.athoracsur.2017.05.022.

Kuzdzal J, Zielinski M, Papla B, et al., 2006, The Transcervical Extended Mediastinal Lymphadenectomy Versus Cervical Mediastinoscopy in Non-Small Cell Lung Cancer Staging. Eur J Cardiothorac Surg, 31:88–94. DOI: 10.1016/j.ejcts.2006.10.026.

Zielinski M, 2010, Transcervical Extended Mediastinal Lymphadenectomy. Thorac Surg Clin, 20:215–23. DOI: 10.1016/j.thorsurg.2010.02.007.

Jawad H, Sirajuddin A, Chung JH, 2013, Review of the International Association for the Study of Lung Cancer Lymph Node Classification System Localization of Lymph Node Stations on CT Imaging. Clin Chest Med, 34:352–63. DOI: 10.1016/j.ccm.2013.04.008.

Benn BS, Parikh M, Tsau PH, et al., 2019, Using a Dedicated Interventional Pulmonology Practice Decreases Wait Time Before Treatment Initiation for New Lung Cancer Diagnoses. Lung, 197:249–55. DOI: 10.1007/s00408-019-00207-6.

Li L, Liu D, Zhang L, et al., 2017, Clinicopathological Features, Diagnoses and Treatments of 6,458 Lung Cancer Patients. Sichuan Da Xue Xue Bao Yi Xue Ban, 48:352–8.

Akalin A, Ergin A, Remiszewski S, et al., 2019, Resolving Interobserver Discrepancies in Lung Cancer Diagnoses by Spectral Histopathology. Arch Pathol Lab Med, 143:157–73. DOI: 10.5858/arpa.2017-0476-SA.

Göke A, Göke R, Ofner A, et al., 2015, The FGFR Inhibitor NVP-BGJ398 Induces NSCLC Cell Death by Activating Caspase-dependent Pathways as well as Caspase-independent Apoptosis. Anticancer Res, 35:5873–9.

Deslauries J, 2012, Mediastinal Lymph Nodes: Ignore? Sample? Dissect? The Role of Mediastinal Node Dissection in the Surgical Management of Primary Lung Cancer. Gen Thorac Cardiovasc Surg, 60:724–34. DOI: 10.1007/s11748-012-0086-3.

De Leyn P, Dooms C, Kuzdzal J, et al., 2014, Revised ESTS Guidelines for Preoperative Mediastinal Lymph Node Staging for Non-Small-Cell Lung Cancer. Eur J Cardiothorac Surg, 45:787–98. DOI: 10.1093/ejcts/ezu028.

Yang H, Yao F, Zhao Y, et al., 2015, Clinical Outcomes of Surgery after Induction Treatment in Patients with Pathologically Proven N2-Positive Stage III Non-Small Cell Lung Cancer. J Thorac Dis, 7:1616–23. DOI: 10.3978/j.issn.2072-1439.2015.09.07.

Eberhardt W, Pottgen C, Gauler T, et al., 2015, Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients with Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). J Clin Oncol, 33:4194–201. DOI: 10.1200/JCO.2015.62.6812.

Dong S, Du J, Li W, et al., 2015, Systematic Mediastinal Lymphadenectomy or Mediastinal Lymph Node Sampling in Patients with Pathological Stage I NSCLC: A Meta-Analysis. World J Surg, 39:410–6. DOI: 10.1007/s00268-014-2804-8.

Wang Y, Wu N, Chen J, et al., 2015, Is Radical Mediastinal Lymphadenectomy Necessary for Elderly Patients with Clinical N-Negative Non-Small-Cell Lung Cancer? A Single Center Matched-pair Study. J Surg Res, 193:435–41. DOI: 10.1016/j.jss.2014.08.018.

Cheng AW, Shaul DB, Sydorak RM, 2015, Successful Thoracoscopic Resection of Large Symptomatic Mediastinal Lymphatic Malformations: Report of 3 Cases. J Thorac Cardiovasc Surg, 150:E59–60. DOI: 10.1016/j.jtcvs.2015.07.020.

Zielinski M, Szlubowski A, Kolodziej M, et al., 2013, Comparison of Endobronchial Ultrasound and/or Endoesophageal Ultrasound with Transcervical Extended Mediastinal Lymphadenectomy for Staging and Restaging of Non-Small-Cell Lung Cancer. J Thorac Oncol, 8:630–6. DOI: 10.1097/JTO.0b013e318287c0ce.

Honguero Martínez AF, García Jiménez MD, García Vicente A, et al., 2016, Ratio of Maximum Standardized Uptake Value of N1 Lymph Nodes in 18F-FDG PET-CT Scan to Tumor Prediction of N2 Disease in Patients with Non-Small Cell Lung Cancer. Rev Esp Med Nucl Imagen Mol, 35:159–64. DOI: 10.1016/j.remnie.2015.08.002.

López Encuentra A, Gómez de la Cámara A, Varela de Ugarte A, et al., 2002, “Will-Rogers” phenomenon. The Definite Criteria of Classification are Applicable to the Staging and Metastasis of Bronchial Lung Cancer. Arch Bronconeumol, 38:166–71. DOI: 10.1016/S0300-2896(02)75183-1.

Cuesta MA, van der Peet DL, Gisbertz SS, et al., 2018, Mediastinal Lymphadenectomy for Esophageal Cancer: Differences Between Two Countries, Japan and the Netherlands. Ann Gastroenterol Surg, 2:176–81. DOI: 10.1002/ags3.12172.

Fabre E, Rivera C, Mordant P, et al., 2015, Evolution of Induction Chemotherapy for Non-Small Cell Lung Cancer over the Last 30 Years: A Surgical Appraisal. Thoracic Cancer, 6:731–40. DOI: 10.1111/1759-7714.12250.

Previous article in this issue

Next article in this issue

Cancer Plus, Electronic ISSN: 2661-3840 Print ISSN: 2661-3832, Published by AccScience Publishing